Ranolazine
Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain. Typically it is used together with other medications when those are insufficient. Benefits appear smaller in women than men. It is taken by mouth.
Clinical data | |
---|---|
Trade names | Ranexa, Aspruzyo Sprinkle, Corzyna |
AHFS/Drugs.com | Monograph |
MedlinePlus | a606015 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 35 to 50% |
Protein binding | ~62% |
Metabolism | Extensive in liver (CYP3A, CYP2D6) and intestine |
Elimination half-life | 1.4 to 1.9 hours |
Excretion | Kidney (75%) and fecal (25%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.149.259 |
Chemical and physical data | |
Formula | C24H33N3O4 |
Molar mass | 427.545 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
Common side effects include constipation, headache, nausea, and dizziness. Serious side effects may include QT prolongation. Use is not recommended in those with liver cirrhosis. How it works is not clear but may involve adenosine triphosphate.
Ranolazine was approved for medical use in the United States in 2006. In 2020, it was the 258th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.